Close
Home - Press releases - Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

Do you have
any question?

Contact us
13/06/2024

Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

#acquisition#china#mesalazine#portfolio

Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from the Chinese Company Jiangsu Anbison Pharmaceutical.

Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

Media enquiries

Please provide a valid state.
Please provide a valid state.
Please provide a valid state.
(+)
Please provide a valid state.
Please provide a valid state.
Please provide a valid state.
*All fields must be filled in

Thank you for your message!
We will examine it with utmost attention and get back to you shortly.